×
0 0 0.0162650602409638 0.0162650602409638 0.0180722891566263 0.0542168674698794 0.039156626506024 0.0620481927710844
Stockreport

Halozyme down 16% premarket on [Seeking Alpha]

HALOZYME THERAPEUTICS (HALO)  More Company Research Source: Seeking Alpha
Last halozyme therapeutics earnings: 2/20 04:05 pm Check Earnings Report
PDF Halozyme down 16% premarket onHalozyme Therapeutics (NASDAQ:HALO) slumps16% premarket on average volume in response to thepublication of an abstract by a research group called SWOG. The results from a meta-analysis of chemotherapy regimens for metastatic pancreatic cancer showed no statistically significant treatment benefit from PEGPH20 added to FOLFIRINOX in terms of overall survival.Previously:Halozyme's PEGPH20 shows no incremental survival benefit in pancreatic cancer study; shares down 11% premarket(March 30, 2017)See all stocks on the move »Now read:Halozyme Therapeutics (HALO) Presents At BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference - Slideshow » [Read more]

IMPACT SNAPSHOT EVENT TIME: HALO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS